+++ Webinar online: Unraveling Kinase Inhibitor Cardiotoxicity with Cardiomyocyte Impedance Assays +++


Hersteller ACEA Biosciences Inc.

Artikel-Nr.: 2801009

Accessories for xCELLigence Systems

Brochures & Applications

Preis auf Anfrage


Die mit einem * markierten Felder sind Pflichtfelder.




xCELLigence CARDIO system is a high-resolution system, utilizing non-invasive impedance readout for real time monitoring of functional beating activity of cardiomyocytes in the wells of E-Plate CARDIO 96. The application range of the xCELLigence system will be extended to the important field of preclinical cardiac safety assessment, cardiac drug screening and basic research.

A Ingenious Solution for in vitro Cardiac Safety Assessment 

The xCELLigence RTCA CARDIO system offers noninvasive impedance measurement of cardiomyocyte contractility in a 96-well microtiter plate format. The system is designed to be placed in a standard tissue culture incubator with physiological temperature, CO2 level and humidity, allowing better controlled assays with both short-term and long-term measurements in real-time.

xCELLigence CARDIO - Cardiomyocite Beating Real-Time Measurement

  • Detection of arrhythmic events
  • Measurement of contractility
  • (Long term) Assessment of cardiomyocyte viability


Key Features

  • Real-time: short (hrs) and long-term (days) assay
  • High throughput impedance assay on 96-well format
  • Dual-mode:
  • - RTCA mode - determination of cell growth status over the assay time
  • - Cardio mode - observation of cardiac beating activity over the assay time


Real-time Monitoring of cardiomyocyte activity in 96-well format
xCELLigence CARDIO, a high resolution system for the non-invasive, label-free real-time monitoring of cardiomyocyte activity in a 96-well format. The compact analyzer work station is put into the incubator, experiment control, data acquisition and evaluation is handled by the analyzer and a PC (laptop) located outside the incubator thus enabling continous data recording.


  • Cardiomyocyte activity measurement in real-time in 96-well E-Plates CARDIO 96
  • Rapid analysis cycles
  • Comprehensive and continous data recording throughout hole experiment (up to weeks)
  • Optimizes timing for compound application and/or downstream assays 
  • Excellent reproducibility and data integrity (<0.3% well failures, <15% intra/inter plate variation)
  • Fully automated data acquisition throughout the whole experiment
  • Long term experiments under controlled physiological conditions in the incubator
  • Compact design of work station, needs only very small space in incubator
  • Easy to handle, intuitive user interface for programming the test protocol
  • Data Analysis software integrated


For more information or Request a Demo, please contact us!

Cardiac Safety in Drug Development

The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative by the FDA seeks to develop a new paradigm for cardiac safety evaluation of new drugs that utilizes high throughput, predictive and mechanistic assays which can identify pro-arrhytmic compounds earlier in the drug discovery process. An important part of this initiative is to use cardiomyocyte model systems together with platforms that can provide incisive information on the pro-arrhythmic risk of compounds. reference:

Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety.Research Consortium. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Am Heart J.2014 Mar;167(3):292- 300.

The development of the xCELLigence CARDIO System was dedicated to optimization and accelaration of drug discovery processes.


Weiterführende Links zu "xCELLigence CARDIO"

Weitere Artikel von ACEA Biosciences Inc.
Ihr Ansprechpartner
E-Mail: josef.freund@ols-bio.de
T +49 421 276 16 9-0
M +49 160 989 33 113

Cardio Analyzer

Cardio Work station

Control Unit (Notebook)

Cardio Software

Cardio Temperature Tool

Protector Shield 96

Resistor Plate Cardio

Accessory Kit (Tools, Spare pins)